Revision of PRECAUTIONS

pregabalin

September 16, 2014

Non-proprietary Name
pregabalin

Safety measure
Precautions should be revised in the package inserts.

In Clinically significant adverse reactions subsection of Adverse Reactions section, the following texts should be added (underlined parts are revised):

**Hepatitis fulminant and hepatic dysfunction:**
Fulminant hepatitis and/or hepatic dysfunction with elevations of aspartate aminotransferase (glutamate oxaloacetate transaminase), alanine aminotransferase (glutamate pyruvate transaminase), etc. may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.